Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in pre-market trading.
